JP2022537384A5 - - Google Patents
Info
- Publication number
- JP2022537384A5 JP2022537384A5 JP2021575509A JP2021575509A JP2022537384A5 JP 2022537384 A5 JP2022537384 A5 JP 2022537384A5 JP 2021575509 A JP2021575509 A JP 2021575509A JP 2021575509 A JP2021575509 A JP 2021575509A JP 2022537384 A5 JP2022537384 A5 JP 2022537384A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- azacitidine
- days
- pharmaceutical composition
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962864413P | 2019-06-20 | 2019-06-20 | |
| US62/864,413 | 2019-06-20 | ||
| PCT/US2020/038760 WO2020257665A1 (en) | 2019-06-20 | 2020-06-19 | Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022537384A JP2022537384A (ja) | 2022-08-25 |
| JP2022537384A5 true JP2022537384A5 (https=) | 2023-06-08 |
Family
ID=71528047
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021575387A Pending JP2022537551A (ja) | 2019-06-20 | 2020-06-19 | ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン |
| JP2021575509A Pending JP2022537384A (ja) | 2019-06-20 | 2020-06-19 | ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021575387A Pending JP2022537551A (ja) | 2019-06-20 | 2020-06-19 | ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220249528A1 (https=) |
| EP (2) | EP3986403A1 (https=) |
| JP (2) | JP2022537551A (https=) |
| KR (2) | KR20220050874A (https=) |
| CN (2) | CN114727996A (https=) |
| AU (2) | AU2020297596A1 (https=) |
| BR (2) | BR112021025537A2 (https=) |
| CA (2) | CA3143719A1 (https=) |
| IL (2) | IL289115A (https=) |
| MX (2) | MX2021015992A (https=) |
| WO (2) | WO2020257671A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013163628A2 (en) | 2012-04-27 | 2013-10-31 | Duke University | Genetic correction of mutated genes |
| US9828582B2 (en) | 2013-03-19 | 2017-11-28 | Duke University | Compositions and methods for the induction and tuning of gene expression |
| WO2016130600A2 (en) | 2015-02-09 | 2016-08-18 | Duke University | Compositions and methods for epigenome editing |
| EP4089175A1 (en) | 2015-10-13 | 2022-11-16 | Duke University | Genome engineering with type i crispr systems in eukaryotic cells |
| KR102787119B1 (ko) | 2015-11-30 | 2025-03-27 | 듀크 유니버시티 | 유전자 편집에 의한 인간 디스트로핀 유전자의 교정을 위한 치료용 표적 및 사용 방법 |
| US20190127713A1 (en) | 2016-04-13 | 2019-05-02 | Duke University | Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use |
| JP7490211B2 (ja) | 2016-07-19 | 2024-05-27 | デューク ユニバーシティ | Ｃｐｆ１に基づくゲノム編集の治療適用 |
| EP3740580A4 (en) | 2018-01-19 | 2021-10-20 | Duke University | GENOME ENGINEERING WITH CRISPR-CAS SYSTEMS IN EUKARYONTS |
| WO2022187288A2 (en) * | 2021-03-01 | 2022-09-09 | Duke University | Systems and methods for genome-wide annotation of gene regulatory elements linked to cell fitness |
| US20250281510A1 (en) * | 2021-04-05 | 2025-09-11 | Pinotbio, Inc. | Combined therapy of 4'-thio-5-aza-2'-deoxycytidine and venetoclax |
| IL308318A (en) * | 2021-05-11 | 2024-01-01 | Abbvie Inc | Dosage regimens of VENETOCLAX for use in the treatment of MYELODYSPLASTIC syndromes in combination with a CYP3A inhibitor and AZACITIDINE |
| IL308321A (en) * | 2021-05-11 | 2024-01-01 | Abbvie Inc | Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine |
| WO2023063784A1 (ko) * | 2021-10-14 | 2023-04-20 | (주)파로스아이바이오 | 2,3,5-치환된 싸이오펜 화합물을 포함하는 병용 투여용 조성물 |
| MX2024008057A (es) | 2021-12-30 | 2024-08-28 | Biomea Fusion Inc | Compuestos de pirazina como inhibidores de flt3. |
| IL317874A (en) | 2022-06-24 | 2025-02-01 | Tune Therapeutics Inc | Compounds, systems and methods for reducing low density lipoproteins through targeted gene suppression |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3692983T3 (pl) * | 2008-05-15 | 2021-12-27 | Celgene Corporation | Doustne formulacje analogów cytydyny i sposoby ich zastosowania |
| KR102400920B1 (ko) * | 2014-05-01 | 2022-05-20 | 셀젠 콴티셀 리서치, 인크. | 리신 특이적 데메틸라제-1의 억제제 |
| AU2015311805B2 (en) | 2014-09-05 | 2020-04-02 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
| MX2017002875A (es) | 2014-09-08 | 2017-05-30 | Celgene Corp | Metodos para tratar una enfermedad o trastorno usando formulaciones orales de analogos de citidina en combinacion con un anticuerpo monoclonal anti-pd1 o anti-pdl1. |
| US10695352B2 (en) | 2015-10-15 | 2020-06-30 | Celgene Corporation | Combination therapy for treating malignancies |
| KR102699521B1 (ko) | 2015-10-15 | 2024-08-26 | 르 라보레또레 쎄르비에르 | 악성 종양의 치료를 위한 조합물 요법 |
| LT3371152T (lt) | 2015-11-05 | 2021-04-12 | Celgene Quanticel Research, Inc. | Kompozicijos, apimančios lizinui specifinės demetilazės-1 inhibitorių, turinčios pirimidino žiedą, ir jų panaudojimas vėžio gydymui |
| CA3017408C (en) | 2016-03-15 | 2025-08-19 | Oryzon Genomics, S.A. | LSD1 INHIBITOR COMBINATIONS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNITIS |
| MA51507A (fr) | 2016-12-09 | 2020-11-11 | Constellation Pharmaceuticals Inc | Marqueurs pour un traitement personnalisé du cancer avec des inhibiteurs de lsd1 |
| KR20200020899A (ko) | 2017-06-30 | 2020-02-26 | 셀진 코포레이션 | 2-(4-클로로페닐)-n-((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-5-일)메틸)-2,2-디플루오로아세트아미드의 조성물 및 사용 방법 |
| CA3069558A1 (en) * | 2017-07-09 | 2019-01-17 | Biosight Ltd. | Combination cancer therapy |
| TWI848030B (zh) * | 2018-12-18 | 2024-07-11 | 比利時商阿根思公司 | Ｃｄ７０組合治療 |
-
2020
- 2020-06-19 JP JP2021575387A patent/JP2022537551A/ja active Pending
- 2020-06-19 WO PCT/US2020/038772 patent/WO2020257671A1/en not_active Ceased
- 2020-06-19 BR BR112021025537A patent/BR112021025537A2/pt not_active IP Right Cessation
- 2020-06-19 CA CA3143719A patent/CA3143719A1/en active Pending
- 2020-06-19 CA CA3143711A patent/CA3143711A1/en active Pending
- 2020-06-19 JP JP2021575509A patent/JP2022537384A/ja active Pending
- 2020-06-19 EP EP20737778.9A patent/EP3986403A1/en active Pending
- 2020-06-19 AU AU2020297596A patent/AU2020297596A1/en not_active Abandoned
- 2020-06-19 EP EP20737783.9A patent/EP3986404A1/en not_active Withdrawn
- 2020-06-19 CN CN202080058723.0A patent/CN114727996A/zh active Pending
- 2020-06-19 CN CN202080057984.0A patent/CN115066243A/zh active Pending
- 2020-06-19 AU AU2020296179A patent/AU2020296179A1/en not_active Abandoned
- 2020-06-19 MX MX2021015992A patent/MX2021015992A/es unknown
- 2020-06-19 US US17/620,541 patent/US20220249528A1/en active Pending
- 2020-06-19 US US17/620,545 patent/US12447171B2/en active Active
- 2020-06-19 WO PCT/US2020/038760 patent/WO2020257665A1/en not_active Ceased
- 2020-06-19 MX MX2021015993A patent/MX2021015993A/es unknown
- 2020-06-19 BR BR112021025375A patent/BR112021025375A2/pt active Search and Examination
- 2020-06-19 KR KR1020227001609A patent/KR20220050874A/ko not_active Ceased
- 2020-06-19 KR KR1020227001605A patent/KR20220024639A/ko not_active Ceased
-
2021
- 2021-12-19 IL IL289115A patent/IL289115A/en unknown
- 2021-12-19 IL IL289110A patent/IL289110A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022537384A5 (https=) | ||
| US6346519B1 (en) | Method and composition for treating arthritis | |
| JP2023088944A5 (https=) | ||
| JP2023503309A5 (https=) | ||
| JP2020503269A5 (https=) | ||
| JP2018507243A5 (https=) | ||
| AR045289A1 (es) | Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento | |
| JP2006516571A5 (https=) | ||
| Huynh et al. | Current concepts in acute pain management | |
| Theofilis et al. | The role of melatonin in chronic kidney disease and its associated risk factors: a new tool in our arsenal? | |
| JP2016505050A5 (https=) | ||
| JP2022553888A5 (https=) | ||
| JP2023522415A5 (https=) | ||
| CN1279582A (zh) | 用于口服的含血清素配方及其使用方法 | |
| WO2010023874A1 (ja) | ロペラミド塩酸塩含有フィルム製剤 | |
| JP2024540439A5 (https=) | ||
| JP2021517128A5 (https=) | ||
| Motamedi et al. | Use of pure nicotine for the treatment of aphthous ulcers | |
| JP2023517130A5 (ja) | Ａｚｄ１６５６又はその薬学的に許容される塩を含む、コロナウイルスによって引き起こされた肺炎及び／又は心筋炎の治療用組成物 | |
| CN104936585B (zh) | 包括苯肾上腺素和扑热息痛的组合药剂 | |
| Vlachou et al. | An account of modified release of melatonin from compression-coated, uncoated and bilayer tablets | |
| JP2024531799A5 (https=) | ||
| JP2025511402A5 (https=) | ||
| JP2025522146A5 (https=) | ||
| JP2025529240A5 (https=) |